Bing

Alexza Pharmaceuticals (NASDAQ:ALXA) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports. The brokerage currently has a $1.25 …
Ticker Report · 8/12/2015
Zacks upgraded shares of Alexza Pharmaceuticals (NASDAQ:ALXA) from a hold rating to a buy rating in a research note issued to investors on Wednesday, MarketBeat reports. Zacks currently has $1.25 price target on the stock. According to Zacks ...
Mideast Times · 8/16/2015
Alexza Pharmaceuticals (NASDAQ:ALXA) was upgraded by Zacks from a “hold” rating to a “buy” rating in a report released on Wednesday, MarketBeat.Com reports. The brokerage currently has a $1.25 price target on the stock. Zacks‘s price target …
wkrb13.com · 8/14/2015
More from Bing News
it goes without saying that the FDA approvals for AEZS and KERX are gong to be HUGE positives by any yardstick. Alexza Pharmaceuticals Inc (NASDAQ: ALXA) is another pharmaceutical company which registered a 17 per cent surge in stock price last …
Smallcap Network · ByBrian Prescott · 3/5/2012
On July 26, 2013, Pres & CEO of Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Thomas Braxton King bought 40,000 shares of ALXA stock at an average price of $4.48. The total transaction amount was $179,200 Thomas B. King has been the President …
Guru Focus · 7/29/2013
Shares of Alexza Pharmaceuticals (NASDAQ:ALXA) opened at 1.03 on Friday. The stock has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.62. The company’s market capitalization is $20.00 million. Alexza …
sleekmoney.com · 8/7/2015
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 10-for-1 reverse split of its common stock. The reverse stock split became effective today at 5:01 p.m. Eastern Time and Alexza's common stock will begin trading on The NASDAQ Global Market …
StreetInsider · 6/12/2012
NEW YORK ( TheStreet) -- Alexza Pharmaceuticals (Nasdaq: ALXA) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating …
The Street · 2/24/2012
ALEXZA PHARMACEUTICALS INC (ALXA): Free Stock Analysis Report ALLOT COMMUNICATIONS LTD ORD (ALLT): Free Stock Analysis Report (A^MID): Free Stock Analysis Report AMR CORP (AAMRQ): Free Stock Analysis Report ANN INC (ANN) …
Yahoo Finance · 7/18/2012
As you might expect, the FDA-induced stress has taken a major toll on the company's stock. ALXA has declined about 65% in the last year alone, and had to perform a reverse 1 to 10 stock split. This move does make a lot of sense in terms of image ...
Seeking Alpha · 9/5/2012